Event aids cancer survivors

“Your doctors should be telling you what’s going on with your bodies…what treatments you’ll be getting.” That’s the diagnosis Susan Hong, MD, director of survivorship at the University of Illinois Cancer Center, recommended to those in attendance at the recent survivorship event titled “Cancer Impacts All of Us: A Conversation with Survivors Panel Discussion, Overview of Clinical Trials, Advocacy and Actions.” Hosted by the University of Illinois Cancer Center’s Patient Brigade, more than…

Continue Reading

Newly activated UI Cancer Center clinical trial

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on ClinicalTrials.gov. For more information or questions about a study, please email cancertrials@uic.edu or call 312-355-5112. S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Sponsor:…

Continue Reading

Benevolenskaya believes mitochondria in pRB key to stopping cancer

It’s in the mitochondria. That’s where University of Illinois Cancer Center member Elizaveta Benevolenskaya believes the secret lies in how the retinoblastoma protein (pRB) stops cancer. Throughout her career, Benevolenskaya has been searching for a protein that explains the differentiation block seen in Rb-deficient cells. “Restoration of normal pRB function is important to stopping cancer from growing,” said Benevolenskaya, associate professor of biochemistry and molecular genetics. “This explains why there is so much…

Continue Reading